IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories.
FAIL · Does not pass the screen
87.00 USD
At the last full screen 2026-08-27
Screened 2026-08-27 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
IRADIMED CORPORATION holds its Markdown at $87.00. The statistical read favours the buyers, held for 4 days.
As held on the ledger · 2026-08-27
Phase
Markdown · caution
Quantitative state
The statistical read favours the buyers, held for 4 days
Price at the screen
$87.00
Valuation
48.60 trailing · 36.10 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.91
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.00%
Below 33%
Interest-bearing debt is just 0.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
59.60%
Below 49%
Money owed to the company is 59.6% of assets, above the 49% limit.
Fail
Revenue purity
2.40%
Below 5%
Only 2.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-27 screen. The gold marker is the market price at the same screen. The price runs 1.7% above the base estimate.
Third-party analyst targets: 2 covering, consensus None. The average target sits +36% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
MRI Pumps Work Well But Trade Too Dear
When an MRI scan needs an IV line most standard pumps must stay outside the room. IRADIMED built the gear that operates safely inside the magnetic field. Yet the shares sit 12 percent above our fair value and carry a forward multiple of 41 times earnings, so we pass.
Revenue is expanding 13 percent a year while margins reach 27 percent and return on equity hits 25 percent. Those figures show a capable niche operator that clears the ethical screen without issue. Still the opportunity rating stays at none because price leaves no margin of safety.
The main risk is paying up for steady but limited growth in a specialised device market. Peak earnings and a stretched multiple often signal a value trap rather than a bargain. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
IRMD trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-02Markdown · changed$87.00-10.3%Entry 5
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 63%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (2 analysts) rates it none, with a mean price target of $118.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 63%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (2 analysts) rates it none, with a mean price target of $118.
2026-07-18Markup$93.60+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 63%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (2 analysts) rates it none, with a mean price target of $118.
2026-07-03Markup$93.60+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$93.60Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
